Herceptin Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
Conditions:   HER2-positive Breast Cancer;   LMD Interventions:   Drug: Tucatinib 150 MG;   Drug: Trastuzumab;   Drug: Capecitabine;   Radiation: Brain & Spinal Radiation Sponsors:   Sunnybrook Health Sciences Centre;   Seagen Inc.;   Viatris Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials